Arca
Skip to content
Tools
Tools

ROS1: Proto-oncogene tyrosine-protein kinase ROS

Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium.

  • Drugs that act on it: 4
  • Approved: 3
  • In phases 1 to 3: 1
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on ROS1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved3

  • Crizotinib
  • Entrectinib
  • Repotrectinib

Phase 30

    Phase 21

    • Taletrectinib

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Proto-oncogene tyrosine-protein kinase ROS inhibitor.
      CrizotinibApprovedPfizerSmall moleculeInhibitor39
      EntrectinibApprovedRocheSmall moleculeInhibitor26
      RepotrectinibApprovedBristol-Myers SquibbSmall moleculeInhibitor8
      TaletrectinibPhase 2Nuvation BioSmall moleculeInhibitor6

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov.
      Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaEntrectinibPhase 2Not yet recruitingSt. Jude Children's Research HospitalNov 4, 2026
      Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid TumorsCrizotinibNot applicableActive, not recruitingNational Cancer Center, KoreaOct 23, 2026
      Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsEntrectinibPhase 2Not yet recruitingShanghai Zhongshan HospitalSep 21, 2026
      A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerCrizotinibPhase 3Not yet recruitingGuangzhou JOYO Pharma Co., LtdSep 11, 2026
      Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaCrizotinibPhase 3RecruitingIDEAYA BiosciencesSep 4, 2026
      Molecularly Tailored Therapy in Advanced Pancreatic CancerCrizotinibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
      Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in JapanRepotrectinib—RecruitingBristol-Myers SquibbAug 10, 2026
      Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibTaletrectinibPhase 1Not yet recruitingNuvation Bio Inc.Aug 3, 2026
      Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionRepotrectinib—Not yet recruitingBristol-Myers SquibbMay 20, 2026
      Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)CrizotinibPhase 1 / Phase 2Not yet recruitingChina Medical University HospitalMay 1, 2026
      A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver FunctionCrizotinibPhase 1Not yet recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.Apr 20, 2026
      Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell CarcinomaCrizotinib—RecruitingFirst People's Hospital of HangzhouOct 3, 2025
      Study on the Mechanism of Acquired Resistance of EntrectinibEntrectinib—RecruitingFudan UniversitySep 30, 2025
      Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib ProgressionEntrectinib, Taletrectinib—Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.Sep 30, 2025
      Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)TaletrectinibPhase 3RecruitingNuvation Bio Inc.Sep 4, 2025
      Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain MetastasesTaletrectinib—RecruitingInnovent Biologics (Suzhou) Co. Ltd.Jun 6, 2025
      Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCCrizotinib, Entrectinib—Not yet recruitingNational Cancer Center, ChinaNov 19, 2024
      Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSEntrectinibPhase 2Not yet recruitingPeking University Shenzhen HospitalNov 18, 2024
      A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsTaletrectinibPhase 3RecruitingNuvation Bio Inc.Aug 21, 2024
      Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCRepotrectinibPhase 2RecruitingCentre Hospitalier Intercommunal de Toulon La Seyne sur MerAug 13, 2024
      Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsEntrectinibPhase 2RecruitingSt. Jude Children's Research HospitalJul 30, 2024
      Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerEntrectinibPhase 2RecruitingWest China HospitalJul 1, 2024
      Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRepotrectinibPhase 2RecruitingMedSIRMar 18, 2024
      A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)RepotrectinibPhase 3Active, not recruitingBristol-Myers SquibbNov 20, 2023
      A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRepotrectinibPhase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer CenterAug 13, 2021
      Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCTaletrectinibPhase 2Active, not recruitingNuvation Bio Inc.Jun 9, 2021
      A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.Sep 19, 2019
      A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.Mar 28, 2017

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Non-small cell lung carcinoma0.71
      • Neoplasm0.61
      • Lung adenocarcinoma0.59
      • Cancer0.54
      • Lung carcinoma0.43
      • Squamous cell lung carcinoma0.39
      • Spitz nevus0.37
      • Melanocytic neoplasm0.37
      • Lymphoid neoplasm0.37
      • Meningothelial Meningioma0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5568, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt P08922, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.